StocksMedium•10 November 2026•
1 min read
Fortress Biotech Signs Exclusive License to Develop IBS-D Treatment FB-607
Key Facts
1Fortress Biotech announced that a majority-owned subsidiary entered into an exclusive licensing agreement with Cedars-Sinai to develop FB-607.
2The new drug candidate, FB-607, is designed to treat symptoms of irritable bowel syndrome with diarrhea (IBS-D).
Fortress Biotech announced that a majority-owned subsidiary entered into an exclusive licensing agreement with Cedars-Sinai to develop FB-607. The new drug candidate is designed to treat symptoms of irritable bowel syndrome with diarrhea (IBS-D), GlobeNewswire reported.
The company aims to expand its gastrointestinal portfolio with the treatment, which is a co-formulation of rifaximin and N-acetylcysteine. Shares of FBIO closed at $1.99 on November 9, 2026, after trading between a low of $1.85 and a high of $2 during that session.